Last reviewed · How we verify
CKD-342
CKD-342 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
CKD-342 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers. Used for Hormone receptor-positive, HER2-negative breast cancer.
At a glance
| Generic name | CKD-342 |
|---|---|
| Also known as | investigational product |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Selective Estrogen Receptor Degrader (SERD) |
| Target | Estrogen Receptor (ER) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CKD-342 functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism is distinct from selective estrogen receptor modulators (SERMs) and provides more complete suppression of estrogen receptor activity. The drug is being developed for hormone receptor-positive breast cancer and other estrogen-dependent malignancies.
Approved indications
- Hormone receptor-positive, HER2-negative breast cancer
Common side effects
- Hot flashes
- Fatigue
- Nausea
- Vaginal dryness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |